Angiotensin receptor blocker attacks armored and cold tumors and boosts immune checkpoint blockade
Jie Mei(Sun Yat-sen University), Yongmei Yin(Nanjing Medical University), Yichao Zhu(Nanjing Medical University), Junying Xu(Wuxi People's Hospital), Zhiwen Luo(Fudan University), Jiayue Yang(Southwest Medical University), Kai Yang(Harbin Medical University), Yun Cai(Jiangsu University), Qing Li(Army Medical University), Qinglin Zhang(Guangdong University of Technology), Yan Zhang(Wuhan University), Jiahui Chu(Jiangsu Province Hospital), Junli Ding, Ning Xue(Jiangsu Province Hospital)
Cited by 28
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
|Journal of Neuroinflammation|2018|268
Natural Coevolution of Tumor and Immunoenvironment in Glioblastoma
|Cancer Discovery|2022|137
Dvl2-Dependent Activation of Daam1 and RhoA Regulates Wnt5a-Induced Breast Cancer Cell Migration
|PLoS ONE|2012|123
PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells
|Nature Communications|2022|116